Your browser doesn't support javascript.
loading
Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
Doan, Tan N; Fox, Greg J; Meehan, Michael T; Scott, Nick; Ragonnet, Romain; Viney, Kerri; Trauer, James M; McBryde, Emma S.
Afiliação
  • Doan TN; Department of Medicine at the Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
  • Fox GJ; Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia.
  • Meehan MT; Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Scott N; Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia.
  • Ragonnet R; The Burnet Institute, Melbourne, Australia.
  • Viney K; Department of Medicine at the Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
  • Trauer JM; The Burnet Institute, Melbourne, Australia.
  • McBryde ES; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
J Antimicrob Chemother ; 74(1): 218-227, 2019 01 01.
Article em En | MEDLINE | ID: mdl-30295760

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rifampina / Análise Custo-Benefício / Tuberculose Latente / Isoniazida / Antituberculosos Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rifampina / Análise Custo-Benefício / Tuberculose Latente / Isoniazida / Antituberculosos Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article